From cancer to birth defects to infectious disease, modern gene and bioanalysis is the key to personalised medicine.
Its goal it to increase the success rate of recovery and minimize side effects by examining the illness and the individual characteristics of a patient as precisely as possible. “analytica has been following advances in personalised medicine for years and will be focusing on this topic once again this year,” says Armin Wittmann, Exhibition Director at analytica, which will take place in Munich on 21–24 June 2022.
Among the nearly 900 exhibitors at the world’s leading trade fair for laboratory technology, analysis and biotechnology, there are representatives from 199 companies from the fields of medicine, healthcare and laboratory diagnostics. There, companies, universities and research institutes will show their innovations for characterising illnesses and therapies, as well as the metabolisms of patients on a molecular level. The spectrum ranges from kits for therapeutic drug monitoring, offered by analytica exhibitor Chromsystems, for example, to mass spectrometry systems for identifying sepsis pathogens and cancer biomarkers in Bruker’s portfolio.
Click on the link below for the full programme.
events.analytica-extended.de/en/conference/
